Comparative Pharmacology
Head-to-head clinical analysis: BLEPH 10 versus FML S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLEPH 10 versus FML S.
BLEPH-10 vs FML-S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking the conversion of p-aminobenzoic acid (PABA) to dihydrofolate, thereby inhibiting bacterial folic acid synthesis and exerting bacteriostatic activity.
Fluorometholone is a synthetic corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2 activity, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production. This results in decreased inflammation, edema, and immune cell infiltration. Sulfacetamide is a sulfonamide antibiotic that competitively inhibits dihydropteroate synthase, blocking folate synthesis and bacterial growth.
Instill 1-2 drops into the conjunctival sac every 3-4 hours, initially up to every 2 hours for severe infections.
1-2 drops of 0.1% ophthalmic suspension into the conjunctival sac every 4 hours; may increase to every 2 hours in severe inflammation.
None Documented
None Documented
Terminal elimination half-life is 60-90 minutes in patients with normal renal function; prolonged in renal impairment.
2.8-3.5 hours; prolonged to 8-12 hours in renal impairment or in neonates
Renal excretion of unchanged drug accounts for approximately 50-70% of the dose; biliary/fecal excretion is minimal (<10%).
Renal (65-75% as unchanged drug and metabolites), biliary/fecal (15-25%)
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic/Corticosteroid Combination